Amgen Inc.
$458.45
+6.62 · +1.47% today
Market open · updated 12:44:26 PM ET
- High
- $453.96 10:40 AM
- Low
- $441.67 9:30 AM
Against the S&P 500 Price change through Oct 27, 2026
AMGN+36.86%
S&P 500+12.87%
AMGN+53.85%
S&P 500+12.32%
AMGN+71.25%
S&P 500+87.41%
AMGN+116.84%
S&P 500+69.55%
Key numbers
- Previous close
- $451.83
- Open
- $465.57
- Day's range
- $457.90 – $468.27
- 52-week range
- $288.00 – $468.27
- Volume
- 946,934
- Average volume
- 2.7 million
- Market value
- $247.9 billion
- Price to earnings
- 27.4last 12 months
- Earnings per share
- $16.19last 12 months
- Beta
- 0.41moves less than the market
- Dividend
- $9.94 a year · 2.24%
- 50-day average
- $418.95
- 200-day average
- $373.42
Tuesday, Nov 3, 2026, after the close.
Analyst price targets and the full financials are in the terminal.
Who Amgen buys from and competes with From our value chain
Amgen in the news
No desk stories on AMGN yet. When we write about it, the story leads this list.
- HeadlineAmgen Q3 Earnings: Will Strong Drug Sales Offset Headwinds?Zacks Investment Research · October 28, 2026 at 12:21 PM ET
- HeadlineAmgen (AMGN) Reports Next Week: Wall Street Expects Earnings GrowthZacks Investment Research · October 27, 2026 at 11:01 AM ET
- HeadlineAmgen vs. Novo Nordisk: Which Healthcare Giant's Stock Is a Better Buy in 2026?The Motley Fool · October 27, 2026 at 10:50 AM ET
- HeadlineAmgen: A Biotech Bargain Heading Into Q3 EarningsSeeking Alpha · October 27, 2026 at 8:22 AM ET
- HeadlineAMGEN APPOINTS DAVID W. GIBBS TO BOARD OF DIRECTORSPRNewsWire · October 26, 2026 at 5:52 PM ET
- HeadlineAmgen vs. Gilead Sciences: Which Biotech Dividend Stock Is the Better Buy?The Motley Fool · October 25, 2026 at 4:26 AM ET
- HeadlineAmgen Inc. (AMGN) Presents at 2026 European Society for Medical Oncology (ESMO) Annual Congress TranscriptSeeking Alpha · October 24, 2026 at 7:17 PM ET
- HeadlineAmgen's IMDELLTRA Cuts Death Risk 58% in Small-Cell Lung Cancer StudyMarketBeat · October 24, 2026 at 7:02 PM ET
Earnings
Next report: Tuesday, Nov 3, 2026, after the close.
Congress trades in AMGN
4 purchases and 4 sales in the latest 8 filings.
| Member | Trade | Amount | Traded | Disclosed |
|---|---|---|---|---|
| Ro KhannaHouse · D-California | Purchase | $1,001 - $15,000 | Sep 4, 2026 | Oct 9, 2026 |
| David TaylorHouse · R-Ohio | Purchase | $1,001 - $15,000 | Sep 22, 2026 | Oct 2, 2026 |
| David TaylorHouse · R-Ohio | Sale | $1,001 - $15,000 | Aug 26, 2026 | Sep 7, 2026 |
| Sheldon WhitehouseSenate · D-Rhode Island | Sale | $1,001 - $15,000 | Aug 12, 2026 | Sep 2, 2026 |
| Tommy TubervilleSenate · R-Alabama | Sale | $15,001 - $50,000 | Apr 15, 2025 | Aug 5, 2026 |
| Ro KhannaHouse · D-California | Purchase | $1,001 - $15,000 | Jun 2, 2026 | Jul 8, 2026 |
| David TaylorHouse · R-Ohio | Purchase | $1,001 - $15,000 | Jun 5, 2026 | Jun 15, 2026 |
| Mark WarnerSenate · D-Virginia | Sale | $1,001 - $15,000 | Apr 7, 2026 | May 1, 2026 |
Source: Periodic transaction reports filed with the House and the Senate · Members disclose ranges, not exact amounts, and may file weeks after the trade.
About Amgen
Amgen Inc., established in 1980 and headquartered in Thousand Oaks, California, is a global biotechnology leader focused on discovering, developing, manufacturing, and delivering groundbreaking human medicines. The company's scientific endeavors span several critical therapeutic categories, including inflammatory conditions, oncology and hematology, bone health, cardiovascular diseases, nephrology, and neuroscience.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Employees
- 31,500
- Headquarters
- Thousand Oaks, California
- Website
- amgen.com
- Listed
- Jun 17, 1983
More drug manufacturers - general stocks
The price refreshes every 15 seconds while the market is open and carries the time it was read. Company figures are updated each evening. Built from WiseView and market data and public filings. For information only, not investment advice.